Raise closed, search for fresh raises on Seedstage

Gaithersburg, MD

Developing and commercializing AI-powered blood tests for early detection of cancer and chronic diseases.

• AI-driven diagnostics: Uses proprietary algorithms combining biomarkers and real-world data.
• Growing market: Positioned in the expanding multi-cancer early detection industry.
• Pending Nasdaq listing: Merger to enable public trading expected in late 2025.
• Accessible testing: Advancing capillary blood collection for easier consumer access.
• Strategic partnerships: Collaborations with major retailers and healthcare providers.

20/20 Biolabs is raising funds to advance the commercialization and development of its AI-powered blood tests aimed at the early detection and prevention of cancers and chronic diseases. The company focuses on making cancer screening more accessible, affordable, and accurate by integrating real-world data with established biomarkers through proprietary AI algorithms. The funds will be used primarily to accelerate sales and marketing efforts and support ongoing research and development, including improvements to AI algorithms and validation of new blood collection techniques that allow easier access to testing through pharmacies and eventually at home.

20/20 Biolabs operates in the rapidly growing multi-cancer early detection market, positioning itself as a leader with patented technology and a strong clinical foundation. The company has a pending merger with a public entity, which will enable its shares to trade on Nasdaq, providing investors with a near-term pathway to liquidity. With increasing government support and expanding use cases, including tests tailored for longevity and healthy aging, 20/20 Biolabs aims to grow revenues significantly while continuing to innovate. Its business model targets employers, consumers, and physician groups, leveraging partnerships to expand market penetration and address a broad need for early cancer detection.

Company Info

20/20 Biolabs develops AI-driven blood tests for early cancer detection and chronic disease prevention.

20/20 Biolabs develops and commercializes AI-powered blood tests focused on early detection and prevention of cancers and chronic diseases. Their flagship product is a multi-cancer early detection (MCED) test that integrates well-established biomarkers with machine learning algorithms to improve accuracy and provide personalized risk assessments. The company operates a CLIA licensed, CAP accredited laboratory and plans to expand its test menu with additional innovative diagnostics including longevity and lifestyle-related tests.

The company is engaged in strategic partnerships and is in the process of merging with a public company, expected to facilitate Nasdaq listing. Their business model targets both employer-paid and consumer-initiated testing markets, with growing adoption in preventative and lifestyle medicine. They leverage affordable proteomic approaches with capillary blood collection to increase accessibility and affordability of their tests. The MCED market is rapidly expanding, supported by legislative initiatives and increasing demand for early cancer detection solutions.